Bristol Myers Squibb Issues Over $20 Billion in New Notes

TL;DR

BMY just dropped over $20B in new debt across multiple maturities.

AI Summary

Bristol Myers Squibb Company announced on November 17, 2025, the issuance of new senior notes. These include $3.857 billion in notes due 2038, $4.581 billion due 2055, $3.363 billion due 2033, $4.289 billion due 2045, and $1.750 billion due 2035. The company also issued $2.973 billion in notes due 2030.

Why It Matters

This significant debt issuance could be for refinancing existing debt, funding acquisitions, or general corporate purposes, impacting the company's capital structure and future financial flexibility.

Risk Assessment

Risk Level: medium — Issuing a large amount of debt increases financial leverage and interest expense, which can pose risks if the company's future earnings do not perform as expected.

Key Numbers

• $3.857B — Notes Due 2038 (Part of a large debt issuance)
• $4.581B — Notes Due 2055 (Part of a large debt issuance)
• $3.363B — Notes Due 2033 (Part of a large debt issuance)
• $4.289B — Notes Due 2045 (Part of a large debt issuance)
• $1.750B — Notes Due 2035 (Part of a large debt issuance)
• $2.973B — Notes Due 2030 (Part of a large debt issuance)

Key Players & Entities

• Bristol Myers Squibb Company (company) — Registrant
• November 17, 2025 (date) — Date of earliest event reported
• $3.857 billion (dollar_amount) — Principal amount of notes due 2038
• $4.581 billion (dollar_amount) — Principal amount of notes due 2055
• $3.363 billion (dollar_amount) — Principal amount of notes due 2033
• $4.289 billion (dollar_amount) — Principal amount of notes due 2045
• $1.750 billion (dollar_amount) — Principal amount of notes due 2035
• $2.973 billion (dollar_amount) — Principal amount of notes due 2030

FAQ

Key Financial Figures

• $0.10 — ange on which registered Common Stock, $0.10 Par Value BMY New York Stock Exchan

Filing Documents

• ef20059419_8k.htm (8-K) — 45KB
• ef20059419_ex99-1.htm (EX-99.1) — 54KB
• ef20059419_ex99-2.htm (EX-99.2) — 80KB
• image0.jpg (GRAPHIC) — 373KB
• image00002.jpg (GRAPHIC) — 3KB
• 0001140361-25-042607.txt ( ) — 916KB
• bmy-20251117.xsd (EX-101.SCH) — 5KB
• bmy-20251117_def.xml (EX-101.DEF) — 20KB
• bmy-20251117_lab.xml (EX-101.LAB) — 30KB
• bmy-20251117_pre.xml (EX-101.PRE) — 22KB
• ef20059419_8k_htm.xml (XML) — 13KB

01

Item 8.01 Other Events. On November 17, 2025, Bristol-Myers Squibb Company ("Bristol Myers Squibb") issued a press release announcing the early participation results, amendment and early settlement of its previously announced cash tender offers (the "Offers") to purchase notes issued by Bristol Myers Squibb. On November 18, 2025, Bristol Myers Squibb also issued a press release announcing the accepted amounts and pricing terms of such previously announced Offers. The Offers are subject to the terms and conditions described in the Offer to Purchase dated November 3, 2025 (as amended or supplemented from time to time), which sets forth a detailed description of the Offers. Copies of the press releases are attached hereto as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K and incorporated herein in their entirety. This Current Report on Form 8-K (including the exhibits attached hereto) is neither an offer to purchase nor a solicitation of an offer to sell any securities. The Offers are made only by, and pursuant to the terms of, the Offer to Purchase. The Offers do not constitute an offer to buy or the solicitation of an offer to sell the notes described herein in any jurisdiction in which such offer or solicitation is unlawful. The Offers are void in all jurisdictions where they are prohibited.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits The following exhibits are included as part of this Current Report on Form 8-K: Exhibit No. Description 99.1 Press release of Bristol-Myers Squibb Company dated November 17, 2025. 99.2 Press release of Bristol-Myers Squibb Company dated November 18, 2025. 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101). 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: November 18, 2025 BRISTOL-MYERS SQUIBB COMPANY By: /s/ Amy Fallone Name: Amy Fallone Title: Senior Vice President and Corporate Secretary 2

View Full Filing

View this 8-K filing on SEC EDGAR